Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| John Douglas French Foundation | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will examine the brain metabolic effects of AC-1202 (Axona®), a medical food for Alzheimer's disease. Subjects who meet entry criteria will undergo H215O positron emission tomography prior to and 90 minutes after consumption of Axona® at baseline and then again after 45 days of treatment. Cognitive testing will also be conducted at baseline and day 45.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| inactive food packet | Placebo Comparator |
| |
| Axona® | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| caprylidene | Dietary Supplement | Axona® is dosed as a 40g packet mixed into 8 oz of liquid (Ensure) for 45 days |
|
| Measure | Description | Time Frame |
|---|---|---|
| Regional cerebral blood flow (rCBF) | At baseline | |
| Regional cerebral blood flow (rCBF) | 90 minutes after initation of treatment with Axona® | |
| Regional cerebral blood flow (rCBF) | 45 days after initation of treatment with Axona® |
| Measure | Description | Time Frame |
|---|---|---|
| Examine differences between ApoE ε4 carriers and noncarriers in changes on rCBF and cognition | At baseline | |
| To examine the effect of AC-1202 on cognition | At baseline | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Joshua Grill, PhD | Mary S. Easton Center for Alzheimer's Disease Research at UCLA | Principal Investigator |
| John Ringman, MD | Mary S. Easton Center for Alzheimer's Disease Research at UCLA | Study Chair |
| Maryam Beigi, MD | Mary S. Easton Center for Alzheimer's Disease Research at UCLA | Study Chair |
| Ellen Woo, PhD | Mary S. Easton Center for Alzheimer's Disease Research at UCLA | Study Chair |
| Dan Silverman, MD, PhD | UCLA Department of Molecular and Medical Pharmacology | Study Chair |
| Cathy Lee, PhD | Mary S. Easton Center for Alzheimer's Disease Research at UCLA | Study Chair |
| Jeffrey Cummings, MD | Mary S. Easton Center for Alzheimer's Disease Research at UCLA | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| 200 Medical Plaza, UCLA Medical Center | Los Angeles | California | 90095 | United States | ||
| Center for Neurotherapeutics at UCLA |
Not provided
| ID | Term |
|---|---|
| D000544 | Alzheimer Disease |
| D003704 | Dementia |
| ID | Term |
|---|---|
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D024801 | Tauopathies |
Not provided
Not provided
| ID | Term |
|---|---|
| C000632241 | caprylidene |
| C538853 | AC-1202 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Dietary Supplement |
|
| Examine differences between ApoE ε4 carriers and noncarriers in changes on rCBF and cognition |
| At 90 minutes after initiation of treatment with Axona® |
| Examine differences between ApoE ε4 carriers and noncarriers in changes on rCBF and cognition | 45 days after initiation of treatment with Axona® |
| To examine the effect of AC-1202 on cognition | At 90 minutes after initiation of treatment with Axona® |
| To examine the effect of AC-1202 on cognition | 45 days after initiation of treatment with Axona® |
| Los Angeles |
| California |
| 90095 |
| United States |
| D019636 |
| Neurodegenerative Diseases |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |